The cost of bringing a dermatological drug to market with approval from the United States Food and Drug Administration (FDA) can cost as much as US$25 million. For this reason, clinical trials are essential for evaluating the safety and efficacy of new drugs and therapies in the field of dermatology. Because the results of these trials can have a significant impact on patient care and treatment, dermatology sponsors must choose outcome measures that are objective, accurate, and relevant to their research question. This is one way to ensure these studies are conducted with the highest level of validity and reliability and their findings can be trusted by other researchers and the public. A key factor in selecting relevant outcome measures in dermatology research lies in the use of appropriate skin assessment tools.
This article explores the role of assessment tools in enhancing the validity and reliability of dermatology clinical trials. From clinical scoring systems to imaging techniques and patient-reported outcome measures, these tools play a vital role in measuring and evaluating trial outcomes objectively. By employing valid and reliable assessment tools, sponsors and contract research organizations (CROs) can generate dependable data, leading to advancements in dermatological care and treatment.
Assessment Tools in Dermatology Clinical Trials
Assessment tools are instruments or procedures used to measure and evaluate the outcome of a clinical trial in an objective, quantifiable manner. The field of clinical dermatology has especially been subject to rapid integration with digitalization, and there are various types of assessment tools, both digital and paper-based, commonly used. Some of these include clinical scoring systems, imaging techniques, and patient-reported outcome measures.
Clinical scoring systems are used to quantitatively summarize the extent and severity of skin diseases as a measure of the response to treatment over time. For example, in patients with atopic dermatitis, dermatologists will apply the Eczema Area and Severity Index (EASI), Severity Scoring of Atopic Dermatitis (SCORAD), and the Investigator’s Global Assessment (IGA) scale. Other disorders like hidradenitis suppurativa and psoriasis have similar scoring systems, named the Acne Inversa Severity Index (AISA) and the Psoriasis Area Severity Index (PASI), respectively.
Imaging techniques such as dermoscopy, photography, and high-frequency ultrasound are also used to visualize and measure skin lesions. Other more qualitative assessment tools include patient-reported outcome measures (PROMs), which rely on the patient’s perception of the disease and its impact on their quality of life. Examples of these include the Dermatology Life Quality Index (DLQI) or Children’s DLQI (CDLQI), Peak Pruritis Numerical Rating Scale (PP-NRS), and Pictorial Representation of Illness & Self-Measure (PRISM).
Validity and Reliability of Assessment Tools
Validity and reliability are two primary characteristics essential to consider in the evaluation of clinical dermatology assessment tools. The validity factor in these tools refers to the extent to which an assessment measures what it is intended to measure, also known as the accuracy of its data. In contrast, reliability refers to the consistency and stability of an assessment’s results over time and across different assessors.
The validity and reliability of assessment tools are especially critical in dermatology clinical trials where patient symptoms must be consistently captured across different sites and investigators. Therefore, those adopted by sponsors and contract research organizations (CROs) to evaluate outcome measures must accurately represent the disease severity and response to treatment. Without the right assessment tools, the resulting data on a new investigational product can be inaccurate, compromising the validity of the clinical trial.
Improving the Validity and Reliability of Assessment Tools
There are various methods to improve the validity and reliability of assessment tools in dermatology clinical trials. One of the most critical approaches is the standardization of assessment procedures to ensure that the same procedures are used consistently across different assessors and different clinical trial sites. Another important method involves the sponsor’s or CRO’s trial team ensuring assessors undergo rigorous training on using the assessment tools correctly and consistently. Training can include holding workshops, online courses, and on-site meetings at clinical trial sites. Other useful approaches include having patients familiarized with any user interfaces for PROMs prior to providing answers, maintaining a consistent environment for participants, and including enough questions to gather reliable data without becoming too lengthy.
In conclusion, the use of valid and reliable outcome measures is essential for conducting successful dermatology clinical trials. By incorporating appropriate assessment tools and ensuring that they are reliable and valid, sponsors and CROs can obtain accurate results from dermatology clinical trials, which ultimately leads to more valuable advances in clinical care and treatment.
The Vial Dermatology CRO
Discover how the Vial Dermatology CRO’s experienced team leverages technology and expertise to deliver high-quality trials and reliable outcome measures. Trusted by leading sponsors, our specialized teams are paving the way for modernized clinical research by leveraging digital innovation to deliver highly reliable and valid outcome measures, shorter study timelines, and a clinical trial experience that puts you first. Contact a team member today to discover how we can help!
